Celgene Corp.

NAS : CELG
Pharmaceuticals
Summit New Jersey
2011 Revenue (US$ Millions)$4,842
2010 Revenue (US$ Millions)$3,626
Revenue Growth (%)33.55%
Net Income (US$ Millions)$1,318
Common Shares Outstanding (Millions)$437
Earnings Per Share (US$)$2.85
Earnings Per Share Growth (%)51.60%
Price To Earnings Ratio23.53
Total Equity (US$ Millions)$5,513
Profit Growth (%)49.7
Profit Margin (%)27.22%
Return On Equity (%)22.03%
Long Term Debt (US$ Millions)$1,276
Debt To Equity Ratio (%)0.23%
Market Capitalization (US$ Millions)$29,574
Total Assets (US$ Millions)$10,006
Return on Assets (%)12.95
Current Assets (US$ Millions)$4,353
Inventories (US$ Millions)$190
Current Liabilities (US$ Millions)$1,540
Cost of Goods Sold (US$ Millions)$426
Asset Turnover0.48
Inventory Turnover1.89